We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioFocus DPI and Medicines for Malaria Venture Collaborate to Identify Anti-Malarial Compounds
News

BioFocus DPI and Medicines for Malaria Venture Collaborate to Identify Anti-Malarial Compounds

BioFocus DPI and Medicines for Malaria Venture Collaborate to Identify Anti-Malarial Compounds
News

BioFocus DPI and Medicines for Malaria Venture Collaborate to Identify Anti-Malarial Compounds

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioFocus DPI and Medicines for Malaria Venture Collaborate to Identify Anti-Malarial Compounds"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioFocus DPI and the not-for-profit organization Medicines for Malaria Venture (MMV) announce the start of a collaboration to identify new natural product and small molecules that demonstrate anti-malarial activity.

Prior to the collaboration announced, MMV had acquired access to BioFocus DPI’s natural product and SoftFocus® compound collections, which gave hits with anti-malarial activity in disease-specific assays.

The aim of the current collaboration is to determine which of the small molecules in these collections show activity, with the intention to further optimize these hits as anti-malarial therapeutics.

“At BioFocus DPI we are pleased that our natural product and SoftFocus collections have yielded hits showing anti-malarial activity in multiple infected erythrocyte assays. These results show how well our libraries are suited for finding new leads in infectious disease,” stated Dr Chris Newton, Senior VP of BioFocus DPI.

“Screening of BioFocus DPI’s compound collections has generated many potential anti-malarial product leads of high quality. This is an exciting find, as MMV is proactively seeking for its portfolio new anti-malarial compounds that can be developed into effective medicines to not only treat the lethal falciparum malaria, but also tackle artemisinin resistance, stop malaria transmission and treat the rarer plasmodium vivax malaria. We look forward to working with BioFocus DPI to develop novel anti-malarial therapeutics that will help ultimately eradicate this fatal disease,” said Tim Wells, Chief Scientific Officer MMV.
Advertisement